Keeping Pace in Oncology: Recent Episodes
ReachMD
Oncology data evolves and emerges at a rapid pace leading to a proliferation of new actionable mutations, therapeutic targets, new therapies, and changes in treatment sequencing. The Keeping Pace in Oncology CME series has been developed to synthesize the latest data from clinical trials to help community oncologists keep pace with the rapid changes and best practices for integrating advances into clinical practice. Educational modules feature conversations with leading experts to explore clinical insights and perspectives on patient-centered treatment.
Host: Heather Wakelee, MD, FASCO
Guest: Lyudmila Bazhenova, MD
We now have FDA approved targeted therapies to treat NSCLC with EGFR exon 20 insertion mutations. Drs. Wakelee and Bazhenova discuss the most current data on both approved therapies and drugs in development.
Guest: Jacob Sands, MD
Host: Charu Aggarwal, MD, MPH
We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.
Host: Susan O’Brien, MD
Guest: Timothy Call, MD
The process of matching the most optimal first-line therapy to patients with CLL has recently undergone a paradigm shift. Along with a widening focus on targeted agents, untangling key patient- and disease-centric parameters adds complexity to this shared decision. Join Drs. Susan O’Brien and Timothy Call as they offer clarity to this first-line decision process—a clarity that you can readily take into the clinic.
Host: Jacob D. Soumerai, MD
Guest: Andrew H. Lipsky, MD
The landscape of treatment for CLL is rapidly evolving, with promising results from trials examining chemotherapy-free regimens in the frontline setting. While these targeted approaches utilizing BTK or BCL-2 inhibitors have largely displaced chemoimmunotherapy in frontline management of CLL, there remains a clinically significant fraction of patients who will require subsequent therapy after developing drug intolerance or progressive disease. Join Drs. Andrew Lipsky and Jacob Soumerai as they strategize which targeted therapeutic options for relapsed/refractory CLL likely offer each individual patient the safest and most effective clinical outcome.
Host: Ian W. Flinn, MD, PhD
Guest: William Wierda, MD
Preventing or mitigating adverse events (AEs) when utilizing small molecule inhibitors of BTK and Bcl-2 in the management of CLL is critical to improving patient outcomes. Coupling each agent’s unique side-effect profile with the appropriate patient makes the decisions even more complex. Join Drs. Ian Flinn and William Wierda as they deep dive into these issues and offer actionable guidance backed by key clinical trials.
Host: Monique Hartley-Brown, MD, MMSc
Guest: Shonali Midha, MD
Significant progress has been made with induction and initial treatment of multiple myeloma, leading to longer and deeper remissions for patients. Yet, how do you decide which regimen is best? Hear how Dr. Monique Hartley-Brown and Dr. Shonali Midha navigate the treatment of their newly diagnosed patients and what factors they consider when selecting a regimen.
Guest: Amrita Krishnan, MD
Guest: Cesar Rodriquez Valdes, MD
There is an unmet clinical need for more durable responses in patients with multiple myeloma because of their inevitable relapses. Advances in our ability to delineate the molecular pathobiology of the disease are guiding impressive new therapeutic options for this patient population. Join Dr. Cesar Rodriguez Valdes and Dr. Amrita Krishnan as they discuss the latest data around emerging agents targeting BCL-2 and BCMA for multiple myeloma and the investigational targets on the horizon.
Host: Shaji K. Kumar, MD
Guest: María-Victoria Mateos, MD, PhD
A plethora of new data for multiple myeloma were presented at ASCO 2022. Hear Dr. Shaji Kuman and Dr. Maria-Victoria Mateos discuss the most relevant findings and which emerging strategies look promising for patients.
Guest: Amrita Krishnan, MD
Guest: Morie Gertz, MD, MACP
Patients with multiple myeloma inevitably experience disease relapse, which is challenging. Rapid therapeutic advances have heralded an increasing number of efficacious targeted strategies and combination therapies for patients after a first relapse or in those with heavily pretreated disease. However, selecting the optimal regimen requires a individualized approach. Hear how Dr. Amrita Krishnan and Dr. Morie Gertz translate the evolving clinical data into their clinical practices and what factors influence their choices to improve durable responses and outcomes for patients with relapsed/refractory multiple myeloma.
Host: Sagar Lonial, MD
Guest: Noopur Raje, MD
Two newly approved BCMA-directed CAR T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are providing patients with the prospect of deep and durable remissions. Maximizing the potential of CAR T cell therapy can provide improved length and quality of life for patients with multiply relapsed multiple myeloma. Join us as Dr. Sagar Lonial and Dr. Noopur Raje discuss the available treatment options, current applications of the clinical data, and strategies to improve care for your patients with multiple myeloma who may be candidates for CAR T cell therapy.
Host: Amer Zeidan, MBBS
Guest: Amy E. DeZern, MD, MHS
MDS is a very heterogenous clonal bone marrow disorder with a high risk for anemia and progression into acute myeloid leukemia. Dr. Amer Zeidan and Dr. Amy DeZern discuss how to appropriately monitor and treat patients with higher-risk MDS.
Host: Andrew M. Brunner, MD
Guest: Amy E. DeZern, MD, MHS
New and novel therapeutics for the treatment myelodysplastic syndrome (MDS) are in development. What are these agents, and how do they work? Listen in as Dr. Andrew Brunner and Dr. Amy DeZern discuss ongoing clinical trials, current data from those trials, and the future potential for tailoring treatment plans.
Since the completion of this activity, the U.S. Food and Drug Administration has lifted the partial clinical hold placed on studies evaluating the investigational agent magrolimab in combination with azacytidine for the treatment of MDS and AML.
https://clinicaltrials.gov/ct2/results?cond=&term=Magrolimab+&cntry=&state=&city=&dist=
Host: Jacqueline Garcia, MD
Guest: David A. Sallman, MD
In order to effectively treat the MDS patient in front of us, we first need to classify their disease and understand its risk stratification category. Hear what Dr. David Sallman and Dr. Jacqueline Garcia have to say about MDS prognosis and risk stratification to better understand each patient’s disease progression.
Host: Mark Socinski, MD
Guest: Vivek Subbiah, MD
RET rearrangements occur in about 1 to 2% of non-small cell lung cancers. Comprehensive genomic testing is critical for identifying these patients and selecting the appropriate treatment option. Find out the exciting progress that has been made with precision oncology in RET+ NSCLC.
Host: Daniel P. Petrylak, MD
Guest: Arlene O. Siefker-Radtke, MD
It's critical that we select and sequence appropriate therapeutics to provide our patients with the best possible outcomes. Dr. Petrylak and Dr. Siefker-Radtke provide a rundown of multiple disease factors to consider, evolving clinical trial data, and the various therapeutic options available in the second and subsequent lines of therapy for patients with locally advanced or metastatic urothelial carcinoma. With so many new treatment options now available and a cure becoming a real possibility, we invite you to tune in to find out if your treatment strategies are on target.
Host: Mark Socinski, MD
Guest: Justin Gainor, MD
With an expanding arena of available selective RET inhibitors and more data being released on emerging therapies, the landscape for patients with RET-positive metastatic NSCLC is evolving rapidly. Join Drs. Mark Socinski and Justin Gainor as they review the importance of molecular testing in every patient, as well as when to initiate the use of selective RET-inhibitors across multiple lines of therapy. Did we mention you should be testing every patient? Tune in to make sure you’re identifying everyone who can benefit from these newer therapies.
Host: Lauren Ritterhouse, MD ,PhD
Guest: Pasi Antero Jänne, MD, PhD
Guest: Kanwal Raghav, MD
HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.
*Since the recording of this activity, clinical trial NCT04479436, patritumab deruxtecan in colorectal cancer, has been terminated early. To learn more about this trial, search for NCT04479436 on ClinicalTrials.gov.
Host: Mark Socinski, MD
Guest: John V. Heymach, MD, PhD
FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.
Host: Ezra Cohen, MD
Guest: Barbara Burtness, MD
Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.
Host: Paul Paik, MD
Guest: Joshua K. Sabari, MD
For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of resistance to EGFR TKI therapy in patients with EGFR-mutated NSCLC, further complicating treatment. Join our case discussion as Dr. Paul Paik and Dr. Josh Sabari highlight the importance of identifying MET gene aberrations in patients with NSCLC.
Host: Paul Paik, MD
Guest: Viola Zhu, MD
Dysregulation of MET signaling has been widely described in oncogenic processes. While all 3 types of MET dysregulation (amplification, overexpression, and gene mutations) have been documented in non-small cell lung cancer (NSCLC), MET exon 14 skipping alterations are a primary oncogenic driver in approximately 3% to 4% of these patients, often with a poor outcome. Join us as Dr. Paul Paik and Dr. Viola Zhu discuss the importance of testing patients for MET gene aberrations and their relevance in the management of NSCLC, especially as related to recently approved and emerging therapies for patients harboring a MET gene aberration.
Host: Richard T. Penson, MD, MRCP
Guest: Ana Oaknin, MD
Therapeutic choices for many women with advanced endometrial cancer are being driven by our understanding of the mismatch repair (deficient/proficient) and microsatellite (instable/stable) status of their tumors. Join us as Dr. Richard Penson and Dr. Ana Oaknin discuss the global perspective surrounding the recent emergence of immunotherapy agents in the management of recurrent or metastatic endometrial cancer. Find out how to manage the toxicities of these newer therapies and discover just how critical a role molecular testing plays in selecting which patients receive a particular therapeutic strategy.
Host: Richard T. Penson, MD, MRCP
Guest: Nicoletta Colombo, MD
Guest: Christine Ghione
Therapeutic options are changing for many patients with advanced endometrial cancer. Join us as Dr. Richard Penson and Dr. Nicoletta Colombo discuss new immunotherapeutic approaches and the importance of a patient’s tumor genomic profile when determining which interventional strategy, they receive. Also hear from Ms. Christine Ghione, a patient advocate, who provides a firsthand perspective of shared decision-making and how the process may be improved.
Since the production of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.
Host: Paul Paik, MD
Guest: Jyoti D. Patel, MD, FASCO
Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.
Host: Floor J. Backes, MD
Guest: Robert L. Coleman, MD, FACOG, FACS
Does immunotherapy play a role in improving quality of life and survival for patients with ovarian cancer? Learn how experts are determining immunotherapy’s place in the treatment plan during the PARP era and what’s on the horizon.
Host: Federico Cappuzzo
Guest: Professor Solange Peters
Guest: Professor Yi-Long Wu
Are dMMR and MSI-H both markers that will soon replace or work in conjunction with PD-L1 when determining immunotherapy for patients with metastatic NSCLC? Accurate testing and treatment selection is critical in identifying patients who will benefit from these therapies. Dr. Federico Cappuzzo, Dr. Solange Peters, and Professor Yi-Long Wu discuss emerging data from the recent WCLC, ESMO, and ASCO virtual conferences and offer their international and regional perspectives on the evolving use of immunotherapies in advanced NSCLC.
Host: Peter Schmid, FRCP, MD, PhD
Guest: Javier Cortes, MD, PhD
Our understanding of the biology of triple-negative breast cancer (TNBC) is leading to the development of more targeted therapies. Dr. Peter Schmid and Dr. Javier Cortés discuss the role of immunotherapies in the treatment of metastatic TNBC and how to determine if your patient is eligible for combination immunotherapies.